Bumrungrad International Hospital
| タイ | トルコ | オーストリア | |
| 肺癌に対する免疫療法 | から $25,000 / 850,000฿ | から $18,000 / 612,000฿ | から $30,000 / 1,020,000฿ |
Bookimedは肺癌に対する免疫療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで肺癌に対する免疫療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。肺癌に対する免疫療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。肺癌に対する免疫療法の旅路でお一人になることはありません。
Leading Thai hospitals including Bumrungrad International, Wattanosoth Cancer Hospital, and MedPark provide advanced immunotherapy for lung cancer. These JCI-accredited facilities offer FDA-approved immune checkpoint inhibitors like pembrolizumab and nivolumab. Treatment involves multidisciplinary teams specializing in precision oncology and personalized molecular testing.
Bookimed Expert Insight: Patients can save significantly by choosing university-affiliated centers like Siriraj Piyamaharajkurun for stage IV treatments. While private centers like Bumrungrad offer faster access and VIP services, specialized public-private wings provide similar drug protocols at a lower monthly cost. Always confirm your PD-L1 biomarker status before traveling to ensure immunotherapy eligibility.
Patient Consensus: Many patients emphasize the importance of bringing physical copies of recent genetic testing. They often report that initial consultations via remote channels help clarify drug availability and total monthly budgets.
Immunotherapy effectively treats lung cancer by boosting the immune system to identify and destroy malignant cells. Success rates reach 50% for high PD-L1 expressing non-small cell lung cancer. This treatment significantly extends 5-year survival rates and offers lower toxicity than traditional chemotherapy for eligible patients.
Bookimed Expert Insight: While many focus on drug costs, the real differentiator in Thailand is molecular diagnostic speed. Top facilities like Bumrungrad International Hospital utilize integrated digital imaging and AI to fast-track biomarker results. This allows patients to start targeted immunotherapy days earlier than at many Western centers. Getting the right drug match quickly is often more critical for outcomes than the specific brand of immunotherapy used.
Patient Consensus: Many patients report significant tumor shrinkage within 6 months, though some highlight the need to monitor thyroid function closely. The reality of pseudoprogression means staying patient is vital, as tumors sometimes appear larger before shrinking successfully.
Immunotherapy for lung cancer commonly causes fatigue, skin rashes, and digestive issues. These immune-related adverse events occur when the stimulated immune system affects healthy tissue. Most reactions are manageable, though serious conditions like pneumonitis require immediate medical evaluation by oncology specialists in JCI-accredited facilities.
Bookimed Expert Insight: Bangkok centers like Bumrungrad International Hospital manage over 1 million patients annually with high-tech monitoring. Their scale allows for specialized teams to track liver enzymes every 2 to 3 weeks. This frequency is vital because immunotherapy side effects can appear up to 2 years after your final dose ends.
Patient Consensus: Many patients describe the exhaustion as a cumulative feeling that worsens with each cycle. They emphasize keeping a detailed diary to catch respiratory changes early.
Thai government schemes primarily cover basic cancer treatments like chemotherapy for citizens, while immunotherapy access remains restricted. International patients and expats generally rely on private insurance or out-of-pocket payments at JCI-accredited facilities like Bumrungrad International Hospital. Most public schemes require standard treatments to fail before considering advanced biologics.
Bookimed Expert Insight: While public schemes limit access, top-tier private hospitals in Bangkok serve over 500,000 international patients annually with seamless insurance coordination. Researching hospitals like Bumrungrad reveals they manage more international claims than most regional centers. Patients often save 61% compared to US costs even when paying entirely out-of-pocket.
Patient Consensus: Many residents report that public funds only cover traditional chemotherapy, leaving them to fund immunotherapy themselves. Patients recommend securing private insurance with specific cancer riders long before a diagnosis to avoid high monthly bills.